Breaking News

Dynport Selects WCCT Global as Strategic Partner

Will support clinical trials evaluating anti-infective drugs

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Dynport Vaccine Co. has selected WCCT Global, a full service CRO, as a strategic partner, along with two other CROs, to support clinical trials evaluating anti-infective drugs with the National Institute of Allergy and Infectious Diseases (NIAID).   WCCT Global will support Phase I studies to demonstrate the safety of investigational therapeutic products being studied by the NIAID and will provide data for appropriate human dosing in later phase development. The therapeutic agents include potent...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters